Safety and Efficacy of Extended-Release Niacin for the Treatment of Dyslipidaemia in Patients with HIV Infection: Aids Clinical Trials Group Study A5148 - Concepedia

Concepedia

Publication | Open Access

Safety and Efficacy of Extended-Release Niacin for the Treatment of Dyslipidaemia in Patients with HIV Infection: Aids Clinical Trials Group Study A5148

DOI Full Paper Access

55

Citations

42

References

2006

Year

Linda Meixner, Julie Hoffman, Beth Zwickl, Mitch Goldman, Kim Whitely, Ann Conrad, Carl J. Fichtenbaum, Fran Hyc, Teresa Spitz, Debra Demarco Shaw,

Antiviral Therapy

Abstract

ERN in doses up to 2,000 mg daily was safe, well-tolerated and efficacious in HIV-infected subjects with atherogenic dyslipidaemia. Increases in glycaemia and insulin resistance tended to be transient.

References

	Year	Citations

Page 1